On September 8, 2021, Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that it has closed a $116 million Series B financing. The financing round was led by Logos Capital and included participation from Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), and Vivo Capital. Founding investor venBio Partners also participated in the financing. Wilson Sonsini Goodrich & Rosati represented Logos Capital in the transaction.

Proceeds from the financing will be used to prepare the advancement of Attralus’ PAR therapeutics into clinical trials. The first PAR therapeutic, AT-03, is expected to begin a Phase 1 biodistribution study in systemic amyloidosis patients. Additionally, the company plans to advance the AT-01 clinical program, an amyloid-specific imaging radiotracer for the diagnosis of systemic amyloidosis. The funding will also enable the company to expand its team and infrastructure to support future growth.

The Wilson Sonsini team that represented Logos Capital in the transaction includes:

Corporate
Dan Koeppen
Meg Burton
Tim Conroy

Intellectual Property
Mike Hostetler

For more information, please see Attralus' press release.